Tolerability of Antihypertensive Medications: The Influence of Age

Hypertension represents one of the leading modifiable risk factors for cardiovascular morbidity and mortality, affecting more than 1.28 billion adults worldwide with increasing prevalence in advancing age [1]. Recent literature has provided clear evidence on the beneficial effects of blood pressure (BP) reduction, also in older adults [2, 3]. Yet, at old age, comorbidities, polypharmacy and age-related changes in pharmacokinetics and pharmacodynamics may contribute to increase the risk of drug-related adverse effects (AEs), i.e., any noxious, undesired, or unintended response to a therapeutic agent, which occur at therapeutic doses [4].

It is estimated that drug-related AEs occur in approximately 20–85% of patients receiving anti-hypertensive medications, with distinct and specific tolerability profiles for different drug classes [5‐7]. AEs associated with antihypertensive medications may negatively impact patient’s compliance [8], leading to poor BP control and increased cardiovascular risk [9].

The HYVET trial reported a 40% prevalence of drug-related AEs among subjects aged 80 or older receiving antihypertensive therapy [10]. Despite the known predisposition of older patients to drug-related AEs, the influence of age on tolerability of antihypertensive medications has been poorly investigated to date, except for the well-known risk of hypotension, electrolyte imbalances and renal function worsening [11, 12]. Therefore, although treatment tolerability can significantly influence patients’ compliance and therapeutic management, the risk and predisposing factors for antihypertensive-related AEs in older adults remain currently unclear [13].

The present study analysed the prevalence and associated factors of antihypertensive-related AEs in a sample of hypertensive outpatients, with the final purpose to investigate the influence of age on antihypertensive treatment tolerability.

We conducted a retrospective cross-sectional analysis of data from all treated hypertensive patients evaluated at the Hypertension Clinic of Careggi University Hospital, Florence, Italy, between January 2017 and July 2020. The Hypertension Clinic of Careggi University Hospital evaluates hypertensive adults of all ages from Florence and its surroundings, offering specialized geriatric care for older hypertensive patients. Tolerability of antihypertensive medications and past history of treatment-related AEs are routinely investigated during the visit and any current/previous AE is recorded in medical charts. For the purpose of the present study, a medical chart review was carried out to collect data on medical history, comorbidities and BP values. Detailed information on medical therapy was recorded, focusing on antihypertensive drug classes (ACE–inhibitors [ACEi], angiotensin receptor blockers [ARBs], calcium channel blockers [CCBs], beta-blockers, diuretics [loop diuretics, thiazide diuretics, mineralcorticoid receptor antagonists], doxazosin and other alpha receptor blockers). Moreover, tolerability of antihypertensive medications was assessed by recording any current/previous AE spontaneously reported by the patient or detected by the physician during routine visits. Antihypertensive-related AEs were defined as any adverse effect resulting in treatment discontinuation or dose reduction. The prevalence of AEs was assessed based on the total number of patients who were receiving or had previously received a specific drug class, i.e., the total number of patients with ongoing treatment and of those with previous treatment discontinuation because of AE (prior treatment).

The study sample included 622 patients (mean age 64.8 ± 14.8 years, 51.4% female). Their characteristics are detailed in Table 1. The study participants were receiving a median number of 2 antihypertensive medications, with renin-angiotensin system inhibitors (79.4%) and CCBs (57.2%) being the most commonly prescribed drug classes.

Table 2 describes antihypertensive-related AEs observed in our study sample. CCB-related ankle swelling (26.8% of patients receiving prior/ongoing CCBs treatment) and ACEi-induced cough (15.1% of patients receiving prior/ongoing ACEi treatment) were the most frequently reported, while other AEs were rare.

CCBs-related ankle swelling was significantly more common in older than in younger patients (35.7% vs 22.3%, p = 0.001), with an OR of 1.94 (95% CI 1.289–2.912, p = 0.002). Prevalence of ACEi-induced cough was similar in the two age groups (13.9% vs 15.6%, p = 0.634) (Fig. 1).

AEs associated with antihypertensive medications represent a common concern for both patients and physicians and might negatively impact treatment compliance and effectiveness. The occurrence and unfavourable consequences of antihypertensive-related AEs might be magnified in older patients, who typically present an increased risk of both cardiovascular events and drug-related AEs [14, 15]. Although some previous studies have investigated antihypertensive-related AEs, data referring to older hypertensive patients remain scarce.

The present study analysed antihypertensive treatment tolerability in a sample of 622 hypertensive outpatients evaluated at a specialised hypertension clinic. The most frequently reported AEs were CCB-related ankle swelling and ACEi-induced cough, also in older patients. Patients aged ≥75 years showed a two-fold increased risk of CCB-related ankle swelling, with approximately one third of patients in this subgroup reporting consequent CCB discontinuation or dose reduction. By contrast, prevalence of ACEi-induced cough was not influenced by age. Other antihypertensive-related AEs were rare both in younger and in older patients.

ACEi-induced cough occurred in the 15.1% of patients receiving ACEi, consistently with previous literature reports [16, 17]. However, available data on ACEi-induced cough are highly variable and inconsistent, due to different characteristics of the study samples and different methods of assessment of AEs. Indeed, some studies reported significantly higher incidence rates [18, 19], while others described a much lower incidence, particularly among patients presenting with chronic cough. Moreover, some data indicate that, in a minority of patients, cough may not recur if ACEi therapy is reintroduced [20‐22]. It follows that cough reported during ACEi treatment may not always be attributable to the drug, and other causes of the symptom should be considered. In our study sample, ACEi-induced cough was found to be associated with GERD independently of other conditions potentially predisposing to cough, such as chronic obstructive pulmonary disease and smoking. This result supports the hypothesis that cough reported during ACEi treatment may be promoted or caused by different clinical conditions, such as GERD. Prospective studies are needed to confirm this hypothesis.

ACEi-induced cough was more common in female patients, confirming previous literature results [23]. We also observed an association between ACEi-induced cough and SNRI antidepressants. To our knowledge, no similar data are available in the literature. A possible explanation involves the mechanism of action of SNRIs, which induce an increase in blood levels of norepinephrine and serotonin. Increased serotonin levels have been described in patients with asthma [24] and a pathogenetic role of serotonin in asthma exacerbations has been hypothesized, although the underlying mechanism remains unknown. We could thus speculate that the increase in serotonin levels induced by SNRIs could favour the occurrence of cough in patients receiving ACEi. However, given the limited number of patients treated with SNRIs in our sample, this association should be further investigated in larger studies.

A randomised controlled trial involving 27,492 hypertensive patients showed an increased risk of ACEi-induced cough in individuals aged 65 or older as compared to younger subjects [25]. The present study did not identify an association between ACEi-induced cough and age, consistently with other literature data [26]. Moreover, the independent association between cough and GERD was confirmed in the older subgroup, implying that ACEi therapy might be only partially causative of this symptom also at old age.

CCB-related ankle swelling was the most common AEs in our sample, being reported by one in four patients receiving CCBs (26.8%). Lower rates have been described in previous studies, ranging from 1 to 15% [27, 28]. Again, this difference might be related to different assessment methods and different clinical characteristics of the studied populations. Our study focused on older hypertensive patients, showing a significantly higher probability of ankle swelling in subjects ≥75 years (35.7% vs 22.2%). Indeed, age was significantly associated with the occurrence of CCB-related ankle swelling, independently of other predisposing conditions and therapies, such as heart failure, venous insufficiency and vasodilators. This finding agrees with previous literature results [29] and might be explained by ageing phenomena of vascular endothelium that promote vascular hyperpermeability [30] and fluid accumulation in interstitial spaces [31]. Moreover, in older patients, concomitant conditions may be present, such as low protein levels, venous insufficiency and heart disease, which further contribute to swelling.

Our results also indicate an independent association between BMI and CCB-related ankle swelling, which was confirmed in the older subgroup. It can be hypothesised that subjects with higher BMI have an increased abdominal pressure which might hamper venous return, predisposing to peripheral swelling. Indeed, an association between BMI and body swelling has been previously described in hypertensive patients [32], although not in reference to CCBs therapy.

It is known that inhibitors of the renin-angiotensin-aldosterone system may reduce the incidence of CCB-related ankle swelling [33, 34], probably due to a reduction of intracapillary hydrostatic pressure [29]. In our study, however, CCB-related swelling was found to be directly and independently associated with ARBs. By contrast, an inverse association was observed between ankle swelling and ACEi, although not confirmed in multivariable analysis. A possible explanation for this result is provided by the different pharmacokinetics of these drug classes. Indeed, ACEi act through a reduction of angiotensin II levels, while ARBs act as antagonists of angiotensin type 1 receptors, thus allowing for and favouring the stimulation of type 2 receptors, which mediate vasodilation and, possibly, vasodilatory oedema [35].

The association between ankle swelling and diuretics was conflicting in our study, showing a direct association with thiazide diuretics in the overall sample and an inverse association with loop diuretics in the older subgroup. The cross-sectional design of our research did not allow to further explore this association. However, it is likely that patients reporting CCB-related swelling had received thiazide diuretics as alternative therapy to achieve blood pressure control. By contrast, a concomitant therapy with loop diuretics might have reduced the risk of swelling in older patients, although a prescriptive cascade (i.e., prescription of loop diuretics to avoid/treat swelling) cannot be excluded.

Other antihypertensive-related AEs were rare in the present study. CCB-induced headache was reported by the 1.8% of the overall sample and by the 0.6% of subjects ≥ 75 years, less frequently than observed in previous studies [17, 36]. Similarly, the occurrence of CCB-related palpitations was uncommon, consistently with a previous meta-analysis [37]. Notably, CCB-related palpitations were not described in any patients of the older subgroup, suggesting an age-related reduction of this AE. Indeed, CCB-related palpitations likely derive from a compensatory heart rate increase induced by vasodilation. It might thus be supposed that this response less commonly occurs at old age, due to a less efficient autonomic nervous system function and blunted chronotropic responses. Constipation related to CCB was observed in the 0.8% of the study population and in the 1.8% of the older subgroup. However, as constipation is common at old age, it cannot be excluded that this drug-related AE might have been underestimated. Gynecomastia was reported by the 3.9% of patients receiving mineralcorticoid receptor antagonists, a lower prevalence than previously described [38]. Gynecomastia was observed only in patients ≥ 75 years, probably due to the reduction of testosterone levels occurring at old age [39, 40].

CCB-related ankle swelling and ACEi-induced cough represent the most common AEs of antihypertensive therapy, also at old age. Older patients showed a two-fold increased risk of CCB-related ankle swelling, that was also independently associated with BMI values. ACEi-induced cough had similar prevalence at young and old ages, being independently associated with gastro-oesophageal reflux disease.